Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors

Magdalena Slosar-Cheah, Poonam Vohra, Manju Prasad, Andrew Fischer, Robert Quinlan, Ashraf Khan

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Insulin-like growth factor mRNA binding protein 3 (IMP3) is an mRNA-binding protein that regulates transcription of insulin-like growth factor II affecting cell proliferation during embryogenesis. It is highly expressed in carcinomas of the pancreas, stomach, colon, rectum, kidneys, uterine cervix, lung, and ovary. The purpose of our study was to evaluate IMP3 expression in thyroid follicular lesions, to determine whether it has a role in differentiating among these lesions, and to understand their biological relationships. We immunostained 219 thyroid lesions selected from our surgical pathology archives including 14 hyperplastic colloid nodules (CN), 19 Hashimoto's thyroiditis (HT), two Graves disease (GD), ten Hürthle cell adenoma (HCA), 20 follicular adenoma (FA), 37 conventional papillary thyroid carcinoma (PTC), 60 follicular variant of papillary carcinoma (FVPC), 19 Hürthle cell carcinoma (HCC), 32 follicular carcinoma (FC), and six poorly differentiated/anaplastic carcinoma. Immunohisto-chemistry was performed on formalin-fixed sections using monoclonal antibody to IMP3. Clinicopathological data were also reviewed. In all cases, residual thyroid tissue, CN, HT, GD, HCA, and FA were completely negative for IMP3 staining. Of the 60 FVPC, 23 tumors (38%) were positive for IMP3, with 13 of these (22%) showing very strong staining (3+). Of the 32 FC, 22 tumors (69%) were positive, with seven (22%) showing very strong staining (3+). Furthermore, 33 out of 37 cases (89%) of PTC were negative for IMP3. In all four PTC cases that did stain positive, staining was weak-moderate (1-2+). Similarly, 15 out of 19 cases (79%) of HCC were negative. No significant correlation was found between pathologic tumor characteristics and IMP3 expression in differentiated follic-ular pattern thyroid carcinoma. With 100% specificity and 69% sensitivity for FC as compared to FA and 100% specificity for FVPC, again compared to FA, IMP3 has the potential to be diagnostically useful in differentiating malignant and benign follicular pattern thyroid lesions. This study also points to a possible common biological relationship between FC and FVPC that requires further investigation.

Original languageEnglish (US)
Pages (from-to)149-157
Number of pages9
JournalEndocrine Pathology
Volume20
Issue number3
DOIs
StatePublished - Sep 2009
Externally publishedYes

Fingerprint

Insulin-Like Growth Factor Binding Protein 3
Thyroid Gland
Adenoma
Carcinoma
Messenger RNA
Carcinoma, Papillary, Follicular
Neoplasms
Hashimoto Disease
Graves Disease
Colloids
Staining and Labeling
Negative Staining
Surgical Pathology
Insulin-Like Growth Factor II
Papillary Carcinoma
Thyroid Neoplasms
Rectum
Cervix Uteri
Formaldehyde
Embryonic Development

Keywords

  • Follicular
  • Immunohistochemistry
  • IMP3
  • Thyroid
  • Tumor

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors. / Slosar-Cheah, Magdalena; Vohra, Poonam; Prasad, Manju; Fischer, Andrew; Quinlan, Robert; Khan, Ashraf.

In: Endocrine Pathology, Vol. 20, No. 3, 09.2009, p. 149-157.

Research output: Contribution to journalArticle

Slosar-Cheah, Magdalena ; Vohra, Poonam ; Prasad, Manju ; Fischer, Andrew ; Quinlan, Robert ; Khan, Ashraf. / Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors. In: Endocrine Pathology. 2009 ; Vol. 20, No. 3. pp. 149-157.
@article{58c44d7770d84b25b527d438607acfec,
title = "Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors",
abstract = "Insulin-like growth factor mRNA binding protein 3 (IMP3) is an mRNA-binding protein that regulates transcription of insulin-like growth factor II affecting cell proliferation during embryogenesis. It is highly expressed in carcinomas of the pancreas, stomach, colon, rectum, kidneys, uterine cervix, lung, and ovary. The purpose of our study was to evaluate IMP3 expression in thyroid follicular lesions, to determine whether it has a role in differentiating among these lesions, and to understand their biological relationships. We immunostained 219 thyroid lesions selected from our surgical pathology archives including 14 hyperplastic colloid nodules (CN), 19 Hashimoto's thyroiditis (HT), two Graves disease (GD), ten H{\"u}rthle cell adenoma (HCA), 20 follicular adenoma (FA), 37 conventional papillary thyroid carcinoma (PTC), 60 follicular variant of papillary carcinoma (FVPC), 19 H{\"u}rthle cell carcinoma (HCC), 32 follicular carcinoma (FC), and six poorly differentiated/anaplastic carcinoma. Immunohisto-chemistry was performed on formalin-fixed sections using monoclonal antibody to IMP3. Clinicopathological data were also reviewed. In all cases, residual thyroid tissue, CN, HT, GD, HCA, and FA were completely negative for IMP3 staining. Of the 60 FVPC, 23 tumors (38{\%}) were positive for IMP3, with 13 of these (22{\%}) showing very strong staining (3+). Of the 32 FC, 22 tumors (69{\%}) were positive, with seven (22{\%}) showing very strong staining (3+). Furthermore, 33 out of 37 cases (89{\%}) of PTC were negative for IMP3. In all four PTC cases that did stain positive, staining was weak-moderate (1-2+). Similarly, 15 out of 19 cases (79{\%}) of HCC were negative. No significant correlation was found between pathologic tumor characteristics and IMP3 expression in differentiated follic-ular pattern thyroid carcinoma. With 100{\%} specificity and 69{\%} sensitivity for FC as compared to FA and 100{\%} specificity for FVPC, again compared to FA, IMP3 has the potential to be diagnostically useful in differentiating malignant and benign follicular pattern thyroid lesions. This study also points to a possible common biological relationship between FC and FVPC that requires further investigation.",
keywords = "Follicular, Immunohistochemistry, IMP3, Thyroid, Tumor",
author = "Magdalena Slosar-Cheah and Poonam Vohra and Manju Prasad and Andrew Fischer and Robert Quinlan and Ashraf Khan",
year = "2009",
month = "9",
doi = "10.1007/s12022-009-9079-x",
language = "English (US)",
volume = "20",
pages = "149--157",
journal = "Endocrine Pathology",
issn = "1046-3976",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors

AU - Slosar-Cheah, Magdalena

AU - Vohra, Poonam

AU - Prasad, Manju

AU - Fischer, Andrew

AU - Quinlan, Robert

AU - Khan, Ashraf

PY - 2009/9

Y1 - 2009/9

N2 - Insulin-like growth factor mRNA binding protein 3 (IMP3) is an mRNA-binding protein that regulates transcription of insulin-like growth factor II affecting cell proliferation during embryogenesis. It is highly expressed in carcinomas of the pancreas, stomach, colon, rectum, kidneys, uterine cervix, lung, and ovary. The purpose of our study was to evaluate IMP3 expression in thyroid follicular lesions, to determine whether it has a role in differentiating among these lesions, and to understand their biological relationships. We immunostained 219 thyroid lesions selected from our surgical pathology archives including 14 hyperplastic colloid nodules (CN), 19 Hashimoto's thyroiditis (HT), two Graves disease (GD), ten Hürthle cell adenoma (HCA), 20 follicular adenoma (FA), 37 conventional papillary thyroid carcinoma (PTC), 60 follicular variant of papillary carcinoma (FVPC), 19 Hürthle cell carcinoma (HCC), 32 follicular carcinoma (FC), and six poorly differentiated/anaplastic carcinoma. Immunohisto-chemistry was performed on formalin-fixed sections using monoclonal antibody to IMP3. Clinicopathological data were also reviewed. In all cases, residual thyroid tissue, CN, HT, GD, HCA, and FA were completely negative for IMP3 staining. Of the 60 FVPC, 23 tumors (38%) were positive for IMP3, with 13 of these (22%) showing very strong staining (3+). Of the 32 FC, 22 tumors (69%) were positive, with seven (22%) showing very strong staining (3+). Furthermore, 33 out of 37 cases (89%) of PTC were negative for IMP3. In all four PTC cases that did stain positive, staining was weak-moderate (1-2+). Similarly, 15 out of 19 cases (79%) of HCC were negative. No significant correlation was found between pathologic tumor characteristics and IMP3 expression in differentiated follic-ular pattern thyroid carcinoma. With 100% specificity and 69% sensitivity for FC as compared to FA and 100% specificity for FVPC, again compared to FA, IMP3 has the potential to be diagnostically useful in differentiating malignant and benign follicular pattern thyroid lesions. This study also points to a possible common biological relationship between FC and FVPC that requires further investigation.

AB - Insulin-like growth factor mRNA binding protein 3 (IMP3) is an mRNA-binding protein that regulates transcription of insulin-like growth factor II affecting cell proliferation during embryogenesis. It is highly expressed in carcinomas of the pancreas, stomach, colon, rectum, kidneys, uterine cervix, lung, and ovary. The purpose of our study was to evaluate IMP3 expression in thyroid follicular lesions, to determine whether it has a role in differentiating among these lesions, and to understand their biological relationships. We immunostained 219 thyroid lesions selected from our surgical pathology archives including 14 hyperplastic colloid nodules (CN), 19 Hashimoto's thyroiditis (HT), two Graves disease (GD), ten Hürthle cell adenoma (HCA), 20 follicular adenoma (FA), 37 conventional papillary thyroid carcinoma (PTC), 60 follicular variant of papillary carcinoma (FVPC), 19 Hürthle cell carcinoma (HCC), 32 follicular carcinoma (FC), and six poorly differentiated/anaplastic carcinoma. Immunohisto-chemistry was performed on formalin-fixed sections using monoclonal antibody to IMP3. Clinicopathological data were also reviewed. In all cases, residual thyroid tissue, CN, HT, GD, HCA, and FA were completely negative for IMP3 staining. Of the 60 FVPC, 23 tumors (38%) were positive for IMP3, with 13 of these (22%) showing very strong staining (3+). Of the 32 FC, 22 tumors (69%) were positive, with seven (22%) showing very strong staining (3+). Furthermore, 33 out of 37 cases (89%) of PTC were negative for IMP3. In all four PTC cases that did stain positive, staining was weak-moderate (1-2+). Similarly, 15 out of 19 cases (79%) of HCC were negative. No significant correlation was found between pathologic tumor characteristics and IMP3 expression in differentiated follic-ular pattern thyroid carcinoma. With 100% specificity and 69% sensitivity for FC as compared to FA and 100% specificity for FVPC, again compared to FA, IMP3 has the potential to be diagnostically useful in differentiating malignant and benign follicular pattern thyroid lesions. This study also points to a possible common biological relationship between FC and FVPC that requires further investigation.

KW - Follicular

KW - Immunohistochemistry

KW - IMP3

KW - Thyroid

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=70449714135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449714135&partnerID=8YFLogxK

U2 - 10.1007/s12022-009-9079-x

DO - 10.1007/s12022-009-9079-x

M3 - Article

C2 - 19449140

AN - SCOPUS:70449714135

VL - 20

SP - 149

EP - 157

JO - Endocrine Pathology

JF - Endocrine Pathology

SN - 1046-3976

IS - 3

ER -